The neuroscience sector took a further step towards consolidation on 19 January with an agreed bid by Acorda Therapeutics Inc for Finland’s Biotie Therapies Oyj which has a late-stage compound for Parkinson’s disease in the clinic and royalty revenue from a product for alcohol dependence. The deal is valued at about $363 million.
